Schizophrenia: Seven-Market Drug Forecast and Market Analysis - Update

1.1 The schizophrenia market will grow to $17.0 billion.
1.2 Key players will struggle to maintain their competitive position.
1.3 While outlook for schizophrenia management made headway, opportunities remain to improve patient outcomes.
1.4 The entry of adjunctive therapies will shape the schizophrenia market.
1.5 What do physicians think?

2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports

3.1 Etiology and Pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.2 Classification or Staging Systems

4.1 Disease background
4.2 Risk factors and comorbidities.
4.3 Global and historical trends
4.4 7MM forecast methodology.
4.4.1 Sources used.
4.4.2 Forecast assumptions and methods.
4.4.3 Forecast assumptions and methods: 12-month total prevalent cases of schizophrenia.
4.5 Epidemiological Forecast for Schizophrenia (2021-31)
4.5.1 12-Month total prevalent cases of schizophrenia
4.5.2 12-Month diagnosed prevalent cases of schizophrenia
4.5.3 Age-specific 12-month diagnosed prevalent cases of schizophrenia.
4.5.4 Sex-specific 12-month diagnosed prevalent cases of schizophrenia.
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of Analysis

5.1 Diagnosis overview
5.2 Treatment overview
5.3 Non-pharmacological management of schizophrenia

6.1 Overview

7.1 Overview
7.2 Development of therapies to target cognitive impairment associated with schizophrenia
7.3 Development of therapies to target negative symptoms.
7.4 Development of therapies for treatment-resistant patients
7.5 Improved patient insight and adherence to treatment

8.1 Overview
8.1.1 Reformulations and innovative drug delivery systems
8.1.2 Novel MOAs
8.1.3 Development of adjunctive therapies
8.1.4 Digital therapeutics
8.2 Clinical trial design
8.2.1 Clinical endpoints
8.2.2 Patient Recruitment

9.1 Overview
9.2 Promising Drugs in Clinical Development

10.1 Overview
10.2 Competitive Assessment

11.1 Overview
11.2 Deal-making trends

12.1 Global Markets
12.1.1 Forecasts
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting Methodology
13.4 Primary Research - KOLs Interviewed for This Report
13.4.1 KOLs and Payers
13.5 Primary Research - Prescriber Survey
13.6 About the Authors
13.6.1 Analyst
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Managing Epidemiologists
13.6.5 Vice President of Disease Analysis and Epidemiology
13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence

• Contact the Publisher

Table 1: Schizophrenia: Key metrics in the 7MM
Table 2: Risk factors and comorbid conditions associated with schizophrenia
Table 3: Treatment Guidelines for Schizophrenia
Table 4: Schizophrenia market - global drivers and barriers, 2021-31
Table 5: Key events impacting sales for schizophrenia in the US, 2021-31
Table 6: Schizophrenia Market - Drivers and Barriers in the US, 2021-31
Table 7: Key events impacting sales for schizophrenia in the 5EU, 2021-31
Table 8: Schizophrenia market - drivers and barriers in the 5EU, 2021-31
Table 9: Key Events Impacting Sales for Schizophrenia in Japan, 2021-31
Table 10: Schizophrenia Market - Drivers and Barriers in Japan, 2021-31
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global sales forecast by country for schizophrenia in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in schizophrenia during the forecast period
Figure 3: Competitive assessment of oral pipeline products that the analyst expects to be licensed for the treatment of schizophrenia during the forecast period
Figure 4: Competitive assessment of pipeline atypical antipsychotic reformulations benchmarked against the SOC, Invega Sustenna
Figure 5: 7MM, 12-month total prevalence (%) of schizophrenia, both sexes, ages =13 years, 2021
Figure 6: 7MM, 12-month diagnosed prevalence (%) of schizophrenia, men and women, ages =13 years, 2021
Figure 7: 7MM, sources used to forecast the 12-month total prevalent cases of schizophrenia
Figure 8: 7MM, sources used and not used to forecast the 12-month diagnosed prevalent cases of schizophrenia
Figure 9: 7MM, 12-month total prevalent cases of schizophrenia, N, both sexes, ages =13 years, 2021
Figure 10: 7MM, 12-month diagnosed prevalent cases of schizophrenia, N, both sexes, ages =13 years, 2021
Figure 11: 7MM, 12-month diagnosed prevalent cases of schizophrenia by age, N, both sexes, 2021
Figure 12: 7MM, 12-month diagnosed prevalent cases of schizophrenia by sex, N, ages =13 years, 2021
Figure 13: Unmet needs and opportunities in schizophrenia
Figure 14: Overview of the development pipeline in schizophrenia
Figure 15: Key late-stage trials for the promising pipeline agents that the analyst expects to be launched for schizophrenia in the 7MM during the forecast period
Figure 16: Competitive assessment of oral pipeline drugs benchmarked against the SOC, Abilify
Figure 17: Competitive assessment of pipeline atypical antipsychotic reformulations benchmarked against the SOC, Invega Sustenna
Figure 18: Analysis of the company portfolio gap in schizophrenia during the forecast period
Figure 19: Global (7MM) sales forecast by country for schizophrenia in 2021 and 2031
Figure 20: Sales forecast by class for schizophrenia in the 7MM in 2021 and 2031
Figure 21: Sales forecast by class for schizophrenia in the US in 2021 and 2031
Figure 22: Sales forecast by class for schizophrenia in the 5EU in 2021 and 2031
Figure 23: Sales forecast by class for schizophrenia in Japan in 2021 and 2031